Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

Antzeko izenburuak

• INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
  nork: Van Den Bent, Martin, et al.
  Argitaratua: (2020)
• LTBK-04 FIRST RESULTS OF THE RANDOMIZED PHASE II STUDY ON DEPATUX –M ALONE, DEPATUX-M IN COMBINATION WITH TEMOZOLOMIDE AND EITHER TEMOZOLOMIDE OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA: FIRST REPORT FROM INTELLANCE 2/EORTC TRIAL 1410
  nork: van den Bent, Martin, et al.
  Argitaratua: (2017)
• ACTR-39. TWO-YEAR RESULTS OF THE INTELLANCE 2/EORTC TRIAL 1410 RANDOMIZED PHASE II STUDY ON DEPATUX–M ALONE, DEPATUX-M COMBINED WITH TEMOZOLOMIDE (TMZ) AND EITHER TMZ OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA (NCT02343406
  nork: van den Bent, Martin, et al.
  Argitaratua: (2018)
• P01.052 Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux -M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406)
  nork: van den Bent, M, et al.
  Argitaratua: (2018)
• QLIF-47. HEALTH RELATED QUALITY OF LIFE AND NEUROLOGICAL DETERIORATION FREE SURVIVAL IN INTELLANCE 2/EORTC TRIAL 1410, A RANDOMIZED PHASE II STUDY ON ABT414 IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA
  nork: Clement, Paul, et al.
  Argitaratua: (2017)